Shares of Zhonghui Bio-B witnessed an astonishing surge of over 170% in Futu's gray market trading, reaching a quoted price of HK$35.16. Dedicated to the research, development, manufacturing, and commercialization of human vaccines, the company boasts a portfolio of core products, encompassing the already-marketed quadrivalent influenza virus subunit vaccine and the ongoing research into a freeze-dried human rabies vaccine.